Clear Street on Dianthus Therapeutics (DNTH): 'We view these data as de-risking'
Tweet Send to a Friend
Clear Street analyst Bill Maughan reiterated a Buy rating and $100.00 price target on Dianthus Therapeutics (NASDAQ: DNTH).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
